Archive position — measured, not model output
0 likes on Devpost
2,264 of the 7,856 archived projects have more likes, and 5,592 share exactly 0 — so this project's #3,281 place in the like-ranked listing is a tie-break inside that group, not a ranking.
Projects (log scale)
Likes on Devpost. ▲ marks this project's group.
Show the figures
| Likes | Projects | Share of archive |
|---|---|---|
| 0 | 5,592 | 71.2% |
| 1 | 1,758 | 22.4% |
| 2 | 285 | 3.6% |
| 3–4 | 132 | 1.7% |
| 5–9 | 75 | 1.0% |
| 10+ | 14 | 0.2% |
Executive Summary
Project: Clariscan
Self-reported basis only, unverified.
The description states that Clariscan is a patient-facing web application designed to simplify complex radiology reports using OCR and locally hosted LLMs. It is presented as an MVP built for the OpenAI 2026 hackathon, with no evidence of revenue, customers or traction beyond its author’s account.
What Changed: The project was submitted as a hackathon entry, indicating initial development and conceptualization. No prior version or evolution is evidenced.
Single Most Important Open Question: Is there any evidence that the product has been used by patients or integrated into healthcare workflows, or whether it has moved beyond an MVP?
What The Product Actually Is
The description states that Clariscan is a patient-facing web application. It uses:
- OCR (via pytesseract) to extract text from uploaded PDFs or images of medical reports.
- Locally hosted LLMs (via Ollama) to generate simplified summaries.
- Angular.js for the frontend.
It is described as an end-to-end solution that converts complex radiology reports into structured, easy-to-understand summaries. The output includes:
- Why the scan was performed
- Key findings in plain language
- An overall summary
- A risk indicator
- A safety disclaimer
The application allows users to download or print these summaries for use during consultations.
Inference: The product is a tool that aims to improve patient understanding of medical reports, not a diagnostic tool. It is built with privacy in mind, using local LLMs and avoiding external APIs.
Positioning & Claim Evolution
The description states that Clariscan was inspired by the gap between receiving a radiology report and consulting a doctor, where patients often feel uncertain and turn to unreliable online sources. The product aims to bridge this gap by offering clear, reliable, and easy-to-understand explanations.
It positions itself as:
- A patient empowerment tool
- A privacy-focused solution (no reliance on external APIs)
- An AI-powered assistant that simplifies medical jargon without replacing professional advice
Inference: The positioning is focused on patient experience and accessibility, not on replacing doctors or becoming a diagnostic platform.
Target Customer & ICP
The description states that Clariscan targets patients who receive radiology reports and are in the period between receiving the report and consulting a doctor. It is described as helping patients feel more informed and less anxious during this time.
It also mentions:
- A potential roadmap to include laboratory reports and other medical documents
- Expansion to multilingual summaries
- Integration with hospitals and diagnostic centers
Inference: The primary ICP appears to be individual patients, but the product may evolve toward healthcare providers or institutions in the future.
Business Model & Pricing Evidence
The description does not state anything about a business model or pricing. It mentions:
- A roadmap that includes secure cloud-based report history for premium users
- Potential integration with hospitals and diagnostic centers via APIs
Inference: The product may evolve toward a freemium or B2B model, but no evidence of current monetization is provided.
Technical & Delivery Signals
The description states:
- Built using Angular.js, OCR (pytesseract), Ollama-LLM, and Python
- Uses locally hosted LLMs to avoid external API reliance
- Designed with a simple and intuitive interface
- Supports PDF or image uploads
- Generates downloadable summaries
Inference: The technical stack is basic but functional for an MVP. The use of local LLMs suggests a focus on privacy, but also implies limitations in scalability or performance.
Traction & Maturity Signals
The description states:
- It was built as an MVP for the OpenAI 2026 hackathon
- It is described as a fully functional MVP
- The team size is 1 person (Mahitha S)
- No evidence of revenue, customers, or adoption beyond the author’s account
Inference: There is no evidence of traction, usage, or market validation. The product remains in an early-stage prototype phase.
Competitive Context
The description does not mention any competitors or similar products. It does not state whether there are existing tools that attempt to simplify medical reports for patients.
Inference: No competitive landscape is evident from the description. Clariscan may be a novel idea, but its uniqueness or market presence cannot be confirmed.
Key Risks & Red Flags
- No traction or usage data: The product is described only as an MVP.
- Single-founder team: Limited capacity for rapid development or scaling.
- Privacy vs. accuracy trade-off: Using local LLMs may limit accuracy, and the risk of misinterpretation remains.
- No commercialization strategy: No pricing, monetization or B2B plans are evident.
- Unverified claims: The product’s effectiveness in reducing anxiety or improving understanding is not substantiated.
Diligence Questions To Ask The Founders
- Has Clariscan been tested with real patients? What feedback have you received?
- How do you plan to ensure the accuracy of AI-generated summaries without overstepping into medical diagnosis?
- Are there any legal or regulatory concerns around using AI to interpret medical reports?
- What is your roadmap for monetization and scaling beyond the MVP stage?
- How do you intend to integrate with hospitals or diagnostic centers, and what are the technical challenges?
Investment/Partnership Verdict
Not evidenced: There is no evidence of revenue, customers, or traction. The project is described as a hackathon MVP with no indication of commercial viability or market readiness.
Confidence Level: Very low — based entirely on self-reported claims and no external validation.
Verdict: Clariscan appears to be an early-stage idea with potential in the patient experience space. However, without evidence of usage, traction, or a clear path to monetization, it is not ready for investment or partnership consideration at this time.
Source
Submitted to the OpenAI 2026 hackathon on Devpost. Project home on DevPost.
The analysis above was generated by a language model from the project's own one-line description. It is not independent research and contains no verified traction, revenue or customer data.
